Memorial Sloan Kettering Cancer Center (MSK) shared a post on LinkedIn:
“In a recent article published in the Harvard Business Review, a new model for accelerating innovation was recommended by leaders within the U.S. academic medical centers (AMC) sector, including Dr. Anaeze Offodile, Chief Strategy Officer at Memorial Sloan Kettering Cancer Center (MSK); Dr. Whitney Snider, Managing Partner of MSK Ventures; Dr. Yashodhara Dash, Vice President of Entrepreneurship & Commercialization at MSK; and Dr. Selwyn Vickers, MSK’s CEO & President.
The model rests upon five core strategies:
- Embrace a new model for accelerating drug development
- Integrate emerging technologies into the drug-development process
- Use strategic partnerships to unlock the value of AI in drug discovery and development
- Extend AMC research investments beyond early-stage science
- Continue to drive global collaborations
As the authors discuss, MSK has partnered with more than 10 companies specializing in AI-driven drug development, enabling frontier algorithms to be deployed throughout each phase of drug testing.
Read more about the article here.”